Phase II evaluation of BAY 43-9006 (NSC-724772) in patients with recurrent or metastatic head and neck cancer.

Trial Profile

Phase II evaluation of BAY 43-9006 (NSC-724772) in patients with recurrent or metastatic head and neck cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2012 Actual end date (1 May 2006) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top